+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Autologous Cell Therapy Market by Source, Application, End User, and by Region - Global Forecast to 2022-2033

  • PDF Icon

    Report

  • 200 Pages
  • January 2023
  • Region: Global
  • Quintana Research and Consulting
  • ID: 5717255
The autologous cell therapy market size is estimated to be USD 5,455.8 million in 2022 and is expected to witness a CAGR of 19.68% during the forecast period 2023-2033. Increase in the number of older people worldwide, and decreased risk of autologous cell treatment rejection are some of the factors contributing to the market growth. Furthermore, surge in the use of autologous cell therapy and increasing prevalence of chronic diseases such cancer, autoimmune diseases, blood disorders, and others are other factors supporting the market growth. However, high capital expenditures and potential for systemic immunological reactions is expected to hinder the growth.

Increasing prevalence of chronic diseases such cancer, autoimmune diseases, blood disorders, and others is predicted to fuel the market growth during the projected period. According to the GLOBOCAN 2020 report from the International Agency for Research on Cancer, which projected the incidence of 36 cancers in 185 countries, there were predicted to be 19,292,789 new cases of cancer diagnosed globally in 2020. Males comprised 10,065,305 of the diagnosed cancer cases, while females comprised 9,227,484 of the cases. By 2040, it was predicted that there will be 15,585,096 cases of cancer in men and 13,302,846 in women. The prevalence of cancer in the world's population is anticipated to fuel market expansion.

Surge in the use of autologous cell therapy is expected to propel the market growth during the forecast period. This therapy is widely used to develop new cancer therapeutics and has produced promising results in numerous trials conducted by researchers across the world to stop the spread of tumorous development. For instance, in May 2022, Autolus plc presented its research findings at the American Society of Gene & Cell Therapy (ASGCT) regarding CAR-T cell therapy to treat cancer by using T cell therapies and avoiding systemic toxicity by using a versatile constitutive cytokine receptor (CCR) system. Similar to this, Autolus Therapeutics plc reports that the RMAT (Regenerative-Medicine Advanced Therapy) designation is given by the U.S. FDA to its CAR-T cell therapy called obecabatagene autoleucel, which is currently undergoing a Phase-II trial and is aimed for use in the treatment of acute lymphocytic leukemia.

Segmentation

By Source

The market is categorized into hematopoietic stem cells, epidermis, bone marrow, mesenchymal stem cells, chondrocytes, and others. In 2022, the bone marrow segment accounted for the highest revenue share due to the fact that various diseases have been effectively treated using bone marrow in autologous cell therapy. One of the main sources for cell therapy is this method, in which the patient's healthy stem cells are extracted from the bone marrow or blood and stored prior to the course of treatment. As an alternative, autologous cell treatment using bone marrow has some advantages over using donor stem cells. The mesenchymal stem cells is expected to have the fastest expansion throughout the course of the projection period due to their preclinical and clinical uses in tissue regeneration and immunological disease therapy. For instance, the Celltex Therapeutics Corporation reported in March 2020 that it has started active discussions with the FDA regarding research employing MSCs to treat the symptoms of COVID-19. The company has also studied the effectiveness and safety of using MSCs for patients with wounds, pain, and diseases related to autoimmune, vascular, and other chronic conditions, such as pneumonia, chronic obstructive pulmonary disease (COPD), and inflammatory lung problems.

By Application

The market is categorized into cardiovascular disorders, wound healing, cancer, autoimmune disorders, neurodegenerative disorders, orthopedics, and others. In the global market, the cancer segment accounted for the largest revenue share in 2022 owing to rising incidence of cancer. Nearly 10 million people died from cancer-related reasons in 2020, according to WHO (World Health Organization). According to the American Cancer Society, 1.9 million new cancer cases were identified and there were 608,570 cancer-related deaths in the United States in 2021. With the rising incidence of cases and desire for therapy, autologous cell therapy is expected to find its greatest demand in cancer applications. Anixa Biosciences reported in August 2022 that it has given the first dose of its FSHR-targeted autologous cell treatment to an ovarian cancer patient in a Phase I trial.

By End User

The market is segmented into academics & research, hospitals & clinics, ambulatory centers, and others. In 2022, the hospitals & clinics segment accounted for the largest revenue share owing to escalating prevalence of cancer, autoimmune disorders, cardiovascular diseases, and neurological diseases as the need for therapy and therapies is growing. The academics & research segment is expected to increase at a significant CAGR over the projected timeframe. There is a large amount of research being conducted on autologous cell treatment and it is gaining more interest globally. The use of live cells in the treatment and prevention of disease is a new scientific field. Research is primarily performed on chondrocytes, mesenchymal stem cells, epidermis, haematopoietic stem cells, bone marrow, and the epidermis. For instance, Allogene Therapeutics reported the results of a recent study of academic institutes in the United States that specialized in the use of CAR T, which revealed that 82% of respondents felt that CAR T therapies have helped in the treatment of cancers.

Regional Markets

In 2022, North America region accounted for the highest revenue in the autologous cell therapy market and is expected to maintain its dominance during the forecast period. This is attributed to the expanding elderly population, a number of immunological benefits, and a lower risk of autologous cell therapy rejection. According to a National Cancer Institute update from October 2021, acute myeloid leukemia is the most prevalent type acute leukemia in adults. A further estimate of 397,501 Americans having leukemia or are in remission, according to statistics from the Leukemia & Lymphoma Society for 2021.The market in this area is quite competitive due to the presence of the majority of the key market participants, including Bristol-Myers Squibb and BrainStorm Cell Therapeutics. Asia Pacific is predicted to expand at the fastest CAGR over the forecast period due to the growing disease burden, active research into autologous cell therapies, and existence of a well-established biotechnology industry.

Competitor Insights

Some of the key players operating in the autologous cell therapy market are Vericel Corporation, Holostem Terapie Avanzate S.R.L, Tego Science, Pharmicell Co. Inc, Opexa Therapeutics, U.S. Stem Cell Inc, Lonza, Novartis, Caladrius Biosciences Inc, Autolus therapeutics, Corning Incorporated, Catalent, Inc, BrainStorm Cell Therapeutics, Bio Elpida, Bristol Myers Squibb, and Sartorius AG.

To achieve a competitive edge, these companies are implementing a variety of growth strategies. Strategic partnerships, alliances, and agreements with different businesses and research institutions are seen to be the main strategies used by companies in this sector.

Aspen Neuroscience, Inc., in collaboration with a number of clinical screening locations in the United States, started the first patient screening trial of its sort in April 2022.

The Stem Cell SpaceShot Grant, which provides US $100,000 in research funding in the fields of stem cell biology and regenerative medicine, was introduced by TreeFrog Therapeutics in April 2022.

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including source, application, and end user from 2023 to 2033.

Segmentation: Autologous Cell Therapy Market Report 2022 - 2033

Source (Revenue, USD Million), 2022 - 2033

  • Hematopoietic Stem Cells
  • Epidermis
  • Bone Marrow
  • Mesenchymal Stem Cells
  • Chondrocytes
  • Others

Application (Revenue, USD Million), 2022 - 2033

  • Cardiovascular Disorders
  • Wound Healing
  • Cancer
  • Autoimmune Disorders
  • Neurodegenerative Disorders
  • Orthopedics
  • Others

End user (Revenue, USD Million), 2022 - 2033

  • Academics & Research
  • Hospitals & Clinics
  • Ambulatory Centers
  • Others

By Region (Revenue, USD Million), 2022 - 2033

North America

  • U.S.
  • Canada

Europe

  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC

Latin America

  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM

Middle East & Africa

  • South Africa
  • GCC
  • Rest of MEA

Table of Contents

1. Research Methodology
1.1. Study Objectives
1.2. Study Scope
1.3. Research Framework
1.3.1. Research Models
1.3.1.1. Bottom-up Approach
1.3.1.2. Top-down Approach
1.3.1.3. Data Triangulation
1.3.2. Data Analysis
1.3.2.1. Data Validation
1.3.2.2. Market Size Estimation
1.3.2.3. Market Forecast Model

2. Introduction: Autologous Cell Therapy

3. Executive Summary

4. Market Dynamics
4.1. Market Drivers
4.1.1. Driver 1
4.1.2. Driver 2
4.1.3. Driver 3
4.1.4. Driver 4
4.2. Market Restraint
4.2.1. Restraint 1
4.2.2. Restraint 2
4.2.3. Restraint 3
4.3. Market Opportunities
4.3.1. Opportunity 1
4.3.2. Opportunity 2
4.3.3. Opportunity 3
4.4. Market Trends
4.4.1. Trend 1
4.4.2. Trend 2
4.4.3. Trend 3
4.5. Market Challenges
4.5.1. Challenge 1
4.5.2. Challenge 2
4.5.3. Challenge 3

5. Market Environment Analysis
5.1. Porter’s 5 Forces Analysis
5.2. PESTEL Analysis
5.3. SWOT Analysis

6. COVID-19 Impact Analysis: Autologous Cell Therapy Market

7. Market Analysis by Source
7.1. Hematopoietic Stem Cells
7.1.1. Hematopoietic Stem Cells Market Forecast, 2022-2033 (USD Million)
7.2. Epidermis
7.2.1. Epidermis Market Forecast, 2022-2033 (USD Million)
7.3. Bone Marrow
7.3.1. Bone Marrow Market Forecast, 2022-2033 (USD Million)
7.4. Mesenchymal Stem Cells
7.4.1. Mesenchymal Stem Cells Market Forecast, 2022-2033 (USD Million)
7.5. Chondrocytes
7.5.1. Chondrocytes Market Forecast, 2022-2033 (USD Million)
7.6. Others
7.6.1. Others Market Forecast, 2022-2033 (USD Million)

8. Market Analysis by Application
8.1. Cardiovascular Disorders
8.1.1. Cardiovascular Disorders Market Forecast, 2022-2033 (USD Million)
8.2. Wound Healing
8.2.1. Wound Healing Market Forecast, 2022-2033 (USD Million)
8.3. Cancer
8.3.1. Cancer Market Forecast, 2022-2033 (USD Million)
8.4. Autoimmune Disorders
8.4.1. Autoimmune Disorders Market Forecast, 2022-2033 (USD Million)
8.5. Neurodegenerative Disorders
8.5.1. Neurodegenerative Disorders Market Forecast, 2022-2033 (USD Million)
8.6. Orthopedics
8.6.1. Orthopedics Market Forecast, 2022-2033 (USD Million)
8.7. Others
8.7.1. Others Market Forecast, 2022-2033 (USD Million)

9. Market Analysis by End User
9.1. Academics & Research
9.1.1. Academics & Research Market Forecast, 2022-2033 (USD Million)
9.2. Hospitals & Clinics
9.2.1. Hospitals & Clinics Market Forecast, 2022-2033 (USD Million)
9.3. Ambulatory Centers
9.3.1. Ambulatory Centers Market Forecast, 2022-2033 (USD Million)
9.4. Others
9.4.1. Others Market Forecast, 2022-2033 (USD Million)

8. Regional Market Analysis
8.1. Regional Market Trends Analysis

9. North America Autologous Cell Therapy Market
9.1. North America Autologous Cell Therapy Market
9.1.1. North America Market Size and Forecast, 2022-2033 (USD Million)
9.1.1.1. Market Size and Forecast by Source, 2022-2033 (USD Million)
9.1.1.2. Market Size and Forecast by Application, 2022-2033 (USD Million)
9.1.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)
9.2. U.S. Autologous Cell Therapy Market
9.2.1. U.S. Market Size and Forecast, 2022-2033 (USD Million)
9.2.1.1. Market Size and Forecast by Source, 2022-2033 (USD Million)
9.2.1.2. Market Size and Forecast by Application, 2022-2033 (USD Million)
9.2.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)
9.3. Canada Autologous Cell Therapy Market
9.3.1. Canada Market Size and Forecast, 2022-2033 (USD Million)
9.3.1.1. Market Size and Forecast by Source, 2022-2033 (USD Million)
9.3.1.2. Market Size and Forecast by Application, 2022-2033 (USD Million)
9.3.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)

10. Europe Autologous Cell Therapy Market
10.1. Europe Autologous Cell Therapy Market
10.1.1. Europe Market Size and Forecast, 2022-2033 (USD Million)
10.1.1.1. Market Size and Forecast by Source, 2022-2033 (USD Million)
10.1.1.2. Market Size and Forecast by Application, 2022-2033 (USD Million)
10.1.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)
10.2. Germany Autologous Cell Therapy Market
10.2.1. Germany Market Size and Forecast, 2022-2033 (USD Million)
10.2.1.1. Market Size and Forecast by Source, 2022-2033 (USD Million)
10.2.1.2. Market Size and Forecast by Application, 2022-2033 (USD Million)
10.2.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)
10.3. UK Autologous Cell Therapy Market
10.3.1. UK Market Size and Forecast, 2022-2033 (USD Million)
10.3.1.1. Market Size and Forecast by Source, 2022-2033 (USD Million)
10.3.1.2. Market Size and Forecast by Application, 2022-2033 (USD Million)
10.3.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)
10.4. France Autologous Cell Therapy Market
10.4.1. France Market Size and Forecast, 2022-2033 (USD Million)
10.4.1.1. Market Size and Forecast by Source, 2022-2033 (USD Million)
10.4.1.2. Market Size and Forecast by Application, 2022-2033 (USD Million)
10.4.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)
10.5. Spain Autologous Cell Therapy Market
10.5.1. Spain Market Size and Forecast, 2022-2033 (USD Million)
10.5.1.1. Market Size and Forecast by Source, 2022-2033 (USD Million)
10.5.1.2. Market Size and Forecast by Application, 2022-2033 (USD Million)
10.5.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)
10.6. Italy Autologous Cell Therapy Market
10.6.1. Italy Market Size and Forecast, 2022-2033 (USD Million)
10.6.1.1. Market Size and Forecast by Source, 2022-2033 (USD Million)
10.6.1.2. Market Size and Forecast by Application, 2022-2033 (USD Million)
10.6.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)
10.7. Rest of Europe Autologous Cell Therapy Market
10.7.1. Rest of Europe Market Size and Forecast, 2022-2033 (USD Million)
10.7.1.1. Market Size and Forecast by Source, 2022-2033 (USD Million)
10.7.1.2. Market Size and Forecast by Application, 2022-2033 (USD Million)
10.7.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)

11. Asia Pacific Autologous Cell Therapy Market
11.1. Asia Pacific Autologous Cell Therapy Market
11.1.1. Asia Pacific Market Size and Forecast, 2022-2033 (USD Million)
11.1.1.1. Market Size and Forecast by Source, 2022-2033 (USD Million)
11.1.1.2. Market Size and Forecast by Application, 2022-2033 (USD Million)
11.1.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)
11.2. Japan Autologous Cell Therapy Market
11.2.1. Japan Market Size and Forecast, 2022-2033 (USD Million)
11.2.1.1. Market Size and Forecast by Source, 2022-2033 (USD Million)
11.2.1.2. Market Size and Forecast by Application, 2022-2033 (USD Million)
11.2.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)
11.3. China Autologous Cell Therapy Market
11.3.1. China Market Size and Forecast, 2022-2033 (USD Million)
11.3.1.1. Market Size and Forecast by Source, 2022-2033 (USD Million)
11.3.1.2. Market Size and Forecast by Application, 2022-2033 (USD Million)
11.3.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)
11.4. India Autologous Cell Therapy Market
11.4.1. India Market Size and Forecast, 2022-2033 (USD Million)
11.4.1.1. Market Size and Forecast by Source, 2022-2033 (USD Million)
11.4.1.2. Market Size and Forecast by Application, 2022-2033 (USD Million)
11.4.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)
11.5. South Korea Autologous Cell Therapy Market
11.5.1. South Korea Market Size and Forecast, 2022-2033 (USD Million)
11.5.1.1. Market Size and Forecast by Source, 2022-2033 (USD Million)
11.5.1.2. Market Size and Forecast by Application, 2022-2033 (USD Million)
11.5.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)
11.6. Australia Autologous Cell Therapy Market
11.6.1. Australia Market Size and Forecast, 2022-2033 (USD Million)
11.6.1.1. Market Size and Forecast by Source, 2022-2033 (USD Million)
11.6.1.2. Market Size and Forecast by Application, 2022-2033 (USD Million)
11.6.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)
11.7. Rest of Asia Pacific Autologous Cell Therapy Market
11.7.1. Rest of Asia Pacific Market Size and Forecast, 2022-2033 (USD Million)
11.7.1.1. Market Size and Forecast by Source, 2022-2033 (USD Million)
11.7.1.2. Market Size and Forecast by Application, 2022-2033 (USD Million)
11.7.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)

12. Latin America Autologous Cell Therapy Market
12.1. Latin America Autologous Cell Therapy Market
12.1.1. Latin America Market Size and Forecast, 2022-2033 (USD Million)
12.1.1.1. Market Size and Forecast by Source, 2022-2033 (USD Million)
12.1.1.2. Market Size and Forecast by Application, 2022-2033 (USD Million)
12.1.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)
12.2. Brazil Autologous Cell Therapy Market
12.2.1. Brazil Market Size and Forecast, 2022-2033 (USD Million)
12.2.1.1. Market Size and Forecast by Source, 2022-2033 (USD Million)
12.2.1.2. Market Size and Forecast by Application, 2022-2033 (USD Million)
12.2.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)
12.3. Mexico Autologous Cell Therapy Market
12.3.1. Mexico Market Size and Forecast, 2022-2033 (USD Million)
12.3.1.1. Market Size and Forecast by Source, 2022-2033 (USD Million)
12.3.1.2. Market Size and Forecast by Application, 2022-2033 (USD Million)
12.3.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)
12.4. Argentina Autologous Cell Therapy Market
12.4.1. Argentina Market Size and Forecast, 2022-2033 (USD Million)
12.4.1.1. Market Size and Forecast by Source, 2022-2033 (USD Million)
12.4.1.2. Market Size and Forecast by Application, 2022-2033 (USD Million)
12.4.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)
12.5. Rest of Latin America Autologous Cell Therapy Market
12.5.1. Rest of Latin America Market Size and Forecast, 2022-2033 (USD Million)
12.5.1.1. Market Size and Forecast by Source, 2022-2033 (USD Million)
12.5.1.2. Market Size and Forecast by Application, 2022-2033 (USD Million)
12.5.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)

13. MEA Autologous Cell Therapy Market
13.1. MEA Autologous Cell Therapy Market
13.1.1. MEA Market Size and Forecast, 2022-2033 (USD Million)
13.1.1.1. Market Size and Forecast by Source, 2022-2033 (USD Million)
13.1.1.2. Market Size and Forecast by Application, 2022-2033 (USD Million)
13.1.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)
13.2. GCC Autologous Cell Therapy Market
13.2.1. GCC Market Size and Forecast, 2022-2033 (USD Million)
13.2.1.1. Market Size and Forecast by Source, 2022-2033 (USD Million)
13.2.1.2. Market Size and Forecast by Application, 2022-2033 (USD Million)
13.2.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)
13.3. South Africa Autologous Cell Therapy Market
13.3.1. South Africa Market Size and Forecast, 2022-2033 (USD Million)
13.3.1.1. Market Size and Forecast by Source, 2022-2033 (USD Million)
13.3.1.2. Market Size and Forecast by Application, 2022-2033 (USD Million)
13.3.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)
13.4. Rest of MEA Autologous Cell Therapy Market
13.4.1. Rest of MEA Market Size and Forecast, 2022-2033 (USD Million)
13.4.1.1. Market Size and Forecast by Source, 2022-2033 (USD Million)
13.4.1.2. Market Size and Forecast by Application, 2022-2033 (USD Million)
13.4.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)

14. Competitor Analysis
14.1. Market Share Analysis, 2022
14.2. Major Recent Developments, 2019-2022

15. Company Profiles
15.1. Vericel Corporation
15.1.1. Company Snapshot
15.1.2. Company Overview
15.1.3. Financial Analysis
15.1.4. Product Benchmarking
15.1.5. Recent Developments
15.2. Holostem Terapie Avanzate S. R. L
15.2.1. Company Snapshot
15.2.2. Company Overview
15.2.3. Financial Analysis
15.2.4. Product Benchmarking
15.2.5. Recent Developments
15.3. Tego Science
15.3.1. Company Snapshot
15.3.2. Company Overview
15.3.3. Financial Analysis
15.3.4. Product Benchmarking
15.3.5. Recent Developments
15.4. Pharmicell Co. Inc
15.4.1. Company Snapshot
15.4.2. Company Overview
15.4.3. Financial Analysis
15.4.4. Product Benchmarking
15.4.5. Recent Developments
15.5. Opexa Therapeutics
15.5.1. Company Snapshot
15.5.2. Company Overview
15.5.3. Financial Analysis
15.5.4. Product Benchmarking
15.5.5. Recent Developments
15.6. U.S. Stem Cell Inc
15.6.1. Company Snapshot
15.6.2. Company Overview
15.6.3. Financial Analysis
15.6.4. Product Benchmarking
15.6.5. Recent Developments
15.7. Lonza
15.7.1. Company Snapshot
15.7.2. Company Overview
15.7.3. Financial Analysis
15.7.4. Product Benchmarking
15.7.5. Recent Developments
15.8. Novartis
15.8.1. Company Snapshot
15.8.2. Company Overview
15.8.3. Financial Analysis
15.8.4. Product Benchmarking
15.8.5. Recent Developments
15.9. Caladrius Biosciences Inc
15.9.1. Company Snapshot
15.9.2. Company Overview
15.9.3. Financial Analysis
15.9.4. Product Benchmarking
15.9.5. Recent Developments
15.10. Autolus therapeutics
15.10.1. Company Snapshot
15.10.2. Company Overview
15.10.3. Financial Analysis
15.10.4. Product Benchmarking
15.10.5. Recent Developments
15.11. Corning Incorporated
15.11.1. Company Snapshot
15.11.2. Company Overview
15.11.3. Financial Analysis
15.11.4. Product Benchmarking
15.11.5. Recent Developments
15.12. Catalent, Inc
15.12.1. Company Snapshot
15.12.2. Company Overview
15.12.3. Financial Analysis
15.12.4. Product Benchmarking
15.12.5. Recent Developments
15.13. BrainStorm Cell Therapeutics
15.13.1. Company Snapshot
15.13.2. Company Overview
15.13.3. Financial Analysis
15.13.4. Product Benchmarking
15.13.5. Recent Developments
15.14. Bio Elpida
15.14.1. Company Snapshot
15.14.2. Company Overview
15.14.3. Financial Analysis
15.14.4. Product Benchmarking
15.14.5. Recent Developments
15.15. Bristol Myers Squibb
15.15.1. Company Snapshot
15.15.2. Company Overview
15.15.3. Financial Analysis
15.15.4. Product Benchmarking
15.15.5. Recent Developments

16. Conclusion

17. Recommendations

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Vericel Corporation
  • Holostem Terapie Avanzate S.R.L
  • Tego Science
  • Pharmicell Co. Inc
  • Opexa Therapeutics
  • U.S. Stem Cell Inc
  • Lonza
  • Novartis
  • Caladrius Biosciences Inc
  • Autolus therapeutics
  • Corning Incorporated
  • Catalent Inc
  • BrainStorm Cell Therapeutics
  • Bio Elpida
  • Bristol Myers Squibb
  • Sartorius AG.